Neurogene is a clinical-stage company developing NGN-401, a one-time gene therapy injected into the brain for Rett syndrome, a rare neurological disorder; it is not approved.
Neurogene's case rests on NGN-401, an investigational Rett gene therapy using EXACT to control MeCP2 expression. All 10 Phase 1/2 participants improved on CGI-I and gained developmental milestones. Embolden must reproduce meaningful benefit: its primary analysis follows the first 24 participants through 12 months, with top-line data expected in the second half of 2027. Manufacturing qualification and cash expected to fund planned operations into the first quarter of 2029 support that path. New preclinical findings support the design rationale without changing the investment case.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Embolden clears its 8-of-24 response bar
Does Embolden meet its composite response requirement with convincing developmental gains and acceptable safety?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
NGN-401's design gains preclinical support; Embolden remains the key clinical milestone
100% response rate in Phase 1/2 sets a high bar for Embolden's single-arm filing — whether that threshold holds at scale decides everything
NGN-401's registrational Embolden trial is fully enrolled; the thesis turns on whether its composite endpoint clears the 33% response bar in H2 2027
NGN-401 bets that durable Phase 1/2 milestone gains in Rett syndrome translate into a BLA-ready registrational readout under FDA's agreed composite endpoint
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neurology and pain
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
3 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.